The subjects are healthy volunteers (excluding those under 20, pregnant women, and lactating women, who were not suffering from any diseases).In addition, studies focusing on mild obesity I with a BMI of 25 to 30 (BMI 23 or higher) will be included. Studies that are relevant to the outcome in question and include participants being treated as patients will be excluded.
Conditions
Interventions
None listed
Sponsors
Ajinomoto AGF, INC.
Review team Mr. Shigeyoshi Fujii, Former employees of Ajinomoto AGF, Inc. Research Collaborator Professor Hiroharu Kamioka, Tokyo University of Agriculture Holders of library librarian qualifications
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: P-Participant:The subjects are healthy volunteers (excluding those under 20, pregnant women, and lactating women, who were not suffering from any diseases).In addition, studies focusing on mild obesity I with a BMI of 25 to 30 (BMI 23 or higher) will be included. Studies that are relevant to the outcome in question and include participants being treated as patients will be excluded. I-Intervention:The intervention condition is oral intake of a test product containing at least 3 g of 'coffee-derived mannooligosaccharides' (any form of intake) for a period of at least 12 weeks. C-Comparison:A comparison was made among one receiving a placebo, another serving as a control group in which food was substituted with food that does not contain 'coffee-derived mannooligosaccharides' and group with no intervention. O-Outcome measurement: Primary outcomes:The primary outcome is reduction in body fat (visceral fat). Specifically, abdominal fat area (amount of change) and abdominal visceral fat area (amount of change) are the primary endpoints. S-Study design:The research designs used in the literature were randomized parallel group controlled trials, quasi-randomized controlled trials, non-randomized controlled trials, and crossover studies. In addition, the languages of presentation were documents written in Japanese and English. In principle, the form of presentation should be an original paper, but short reports and reports may be accepted if the content can be identified. To avoid publication bias, studies that include results published in clinical trial registration databases are also eligible. For the time period, studies published from the first time the databases were opened or loaded to the date of the search will be included in the search.
Exclusion criteria
Exclusion criteria: Abstracts of conference presentations (conference proceedings) will be excluded they are considered insufficiently descriptive. Other gray documents will be excluded it is difficult to confirm their appropriateness.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome is reduction in body fat (visceral fat). Specifically, abdominal fat area (amount of change) and abdominal visceral fat area (amount of change) are the primary endpoints. Both are presented as means and standard deviations with respect to the amount of change. | — |
Secondary
| Measure | Time frame |
|---|---|
| Key secondary outcomes are body fat percentage, body fat mass (DEXA, MRI, etc.), BMI, body weight, and waist circumference. | — |
Countries
Japan
Contacts
Public ContactYuki Ishitani
Ajinomoto AGF, INC. Technology Development Dept. Technical Research and Development Institute
Outcome results
None listed